Who are Levofloxacin-Amox/clav.'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Levofloxacin + Ceftriaxone.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/levofloxacin-amox-clav.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Levofloxacin-Amox/clav. — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Levofloxacin-Amox/clav. (Levofloxacin-Amox/clav.) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Fluoroquinolone + Beta-lactam/Beta-lactamase inhibitor combination. Area: Infectious Disease.

marketed Fluoroquinolone + Beta-lactam/Beta-lactamase inhibitor combination Bacterial DNA gyrase, topoisomerase IV, penicillin-binding proteins Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Levofloxacin-Amox/clav. (Levofloxacin-Amox/clav.) — Buddhist Tzu Chi General Hospital. This is a fixed-dose combination of levofloxacin (a fluoroquinolone antibiotic) and amoxicillin/clavulanic acid (a beta-lactam with beta-lactamase inhibitor) that together provide broad-spectrum bacterial coverage through inhibition of DNA gyrase and bacterial cell wall synthesis.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Levofloxacin-Amox/clav. TARGET	Levofloxacin-Amox/clav.	Buddhist Tzu Chi General Hospital	marketed	Fluoroquinolone + Beta-lactam/Beta-lactamase inhibitor combination	Bacterial DNA gyrase, topoisomerase IV, penicillin-binding proteins
Levofloxacin + Ceftriaxone	Levofloxacin + Ceftriaxone	Bayer	phase 3	Fluoroquinolone + Third-generation cephalosporin combination	Bacterial DNA gyrase, topoisomerase IV, penicillin-binding proteins

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Fluoroquinolone + Beta-lactam/Beta-lactamase inhibitor combination class)

Buddhist Tzu Chi General Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Levofloxacin-Amox/clav. — Competitive Intelligence Brief. https://druglandscape.com/ci/levofloxacin-amox-clav. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab